SIGA Technologies, Inc. is a pharmaceutical company that specializes in developing and commercializing solutions for serious unmet medical needs, particularly in the area of biodefense.
Their primary product is TPOXX, an oral antiviral drug approved for the treatment of smallpox. This focus on innovative antiviral and infectious disease treatments aims to address evolving health threats and bioterrorism risks.
